Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3069 |
Name | malignant astrocytoma |
Definition | A malignant glioma that is has_material_basis_in astrocyte cells, a type of star-shaped glial cell, located in the brain and spinal cord. |
Source | DiseaseOntology.org |
Alt Ids | DOID:4861 |
Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
IDH1 mutant | N/A | malignant astrocytoma | not applicable | detail... |
IDH2 mutant | N/A | malignant astrocytoma | not applicable | detail... |
IDH1 R132H | IDH1 R132H peptide vaccine | malignant astrocytoma | predicted - sensitive | detail... |
IDH1 R132H | Temozolomide | malignant astrocytoma | predicted - sensitive | detail... |
IDH1 act mut | Ivosidenib | malignant astrocytoma | sensitive | detail... |
IDH2 act mut | Ivosidenib | malignant astrocytoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00301418 | Phase Ib/II | Erlotinib | Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma | Completed | USA | 0 |
NCT00492687 | Phase II | Carboplatin Temozolomide Tamoxifen | Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas | Unknown status | USA | 0 |
NCT00906516 | Phase II | 81C6 + Bevacizumab | Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme | Unknown status | USA | 0 |
NCT00968240 | Phase I | Bevacizumab | Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) | Completed | USA | 0 |
NCT01052363 | Phase I | Bevacizumab + Fosbretabulin | OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas | Withdrawn | USA | 0 |
NCT01130077 | Phase I | Poly ICLC | A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas | Active, not recruiting | USA | 0 |
NCT01140568 | Phase II | Nilotinib | Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas | Completed | USA | 0 |
NCT01188096 | Phase II | Poly ICLC | A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas | Completed | USA | 0 |
NCT01238237 | Phase I | Cetuximab | Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma | Completed | USA | 0 |
NCT01266031 | Phase Ib/II | Bevacizumab + Vorinostat Bevacizumab | Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | Completed | USA | 0 |
NCT01269853 | Phase Ib/II | Bevacizumab | Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | Recruiting | USA | 0 |
NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
NCT01339039 | Phase I | Bevacizumab + Plerixafor | Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | Terminated | USA | 0 |
NCT01386710 | Phase Ib/II | Bevacizumab + Carboplatin | Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma | Suspended | USA | 0 |
NCT01392209 | Phase I | Bevacizumab | Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma | Completed | USA | 0 |
NCT01403610 | Phase II | Bevacizumab + Evofosfamide Evofosfamide | Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab | Completed | USA | 0 |
NCT01434602 | Phase Ib/II | Everolimus + Sorafenib | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | Completed | USA | 0 |
NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | DNK | CAN | 0 |
NCT01721577 | Phase Ib/II | AXL1717 | Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas | Terminated | USA | 0 |
NCT01734512 | Phase II | Everolimus | PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children | Completed | USA | 0 |
NCT01884740 | Phase Ib/II | Bevacizumab + Cetuximab | Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age | Terminated | USA | 0 |
NCT01891747 | Phase I | Bevacizumab + Temozolomide | A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma | Completed | USA | 0 |
NCT01999270 | Phase I | Bevacizumab + Irinotecan | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors | Completed | USA | 0 |
NCT02100891 | Phase II | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors | Completed | USA | 0 | |
NCT02101905 | Phase I | Lapatinib | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | Completed | USA | 0 |
NCT02238496 | Phase II | Perifosine + Temsirolimus | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | Completed | USA | 0 |
NCT02372006 | Phase Ib/II | Afatinib | Trial of Afatinib in Pediatric Tumours | Completed | USA | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUT | AUS | 1 |
NCT02423525 | Phase I | Afatinib | Safety Study of Afatinib for Brain Cancer | Completed | USA | 0 |
NCT02490930 | Phase I | Fingolimod | A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma | Completed | USA | 0 |
NCT02529072 | Phase I | Nivolumab | Nivolumab With DC Vaccines for Recurrent Brain Tumors | Completed | USA | 0 |
NCT02549833 | Phase I | GBM6-AD lysate protein vaccine + Poly ICLC | Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma | Active, not recruiting | USA | 0 |
NCT02607124 | Phase Ib/II | Ribociclib | Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | Terminated | USA | 0 |
NCT02885324 | Phase II | Cabozantinib | Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children | Terminated | USA | 0 |
NCT02924038 | Phase I | IMA950 + Poly ICLC Varlilumab | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | Terminated | USA | 0 |
NCT02942264 | Phase Ib/II | Zotiraciclib Temozolomide + Zotiraciclib | TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | Completed | USA | 0 |
NCT03011671 | Phase I | Acetazolamide + Temozolomide | Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma | Recruiting | USA | 0 |
NCT03032484 | Phase II | Bevacizumab Bevacizumab + TVB-2640 | TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma | Completed | USA | 0 |
NCT03220646 | Phase II | Abemaciclib | Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | Active, not recruiting | USA | 0 |
NCT03332355 | Phase I | PAC-1 + Temozolomide | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 | Terminated | USA | 0 |
NCT03343197 | Phase I | Ivosidenib Vorasidenib | Study of AG-120 and AG-881 in Subjects With Low Grade Glioma | Active, not recruiting | USA | 0 |
NCT03514069 | Phase I | Ruxolitinib Ruxolitinib + Temozolomide | Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma | Active, not recruiting | USA | 0 |
NCT03528642 | Phase I | Radiotherapy + Telaglenastat + Temozolomide | Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma | Active, not recruiting | USA | 0 |
NCT03596086 | Phase Ib/II | HSV-Tk + Valacyclovir | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | Recruiting | USA | 0 |
NCT03603405 | Phase Ib/II | HSV-Tk | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | Recruiting | USA | 0 |
NCT03605550 | Phase I | Unesbulin | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | Active, not recruiting | USA | 0 |
NCT03696355 | Phase I | GDC-0084 | Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas | Completed | USA | 0 |
NCT03871257 | Phase III | Carboplatin + Vincristine Sulfate Selumetinib | A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma | Recruiting | USA | CAN | 1 |
NCT03896568 | Phase I | DNX-2401 | MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | Recruiting | USA | 0 |
NCT03919071 | Phase II | Dabrafenib + Trametinib | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | Recruiting | USA | 1 |
NCT03975829 | FDA approved | Dabrafenib + Trametinib | Pediatric Long-Term Follow-up and Rollover Study | Active, not recruiting | USA | SWE | NLD | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 2 |
NCT04164901 | Phase III | Vorasidenib | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) | Active, not recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | 1 |
NCT04166409 | Phase III | Selumetinib Carboplatin + Vincristine Sulfate | A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma | Recruiting | USA | CAN | 1 |
NCT04197934 | Phase I | WSD0922 | WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases | Recruiting | USA | 0 |
NCT04576117 | Phase III | Selumetinib Selumetinib + Vinblastine | A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma | Recruiting | USA | CAN | 0 |
NCT04704154 | Phase II | Nivolumab + Regorafenib | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Completed | USA | ITA | GBR | FRA | BEL | 3 |
NCT04908176 | Phase I | Avapritinib + Midazolam | A Drug-drug Interaction Study of Avapritinib and Midazolam | Active, not recruiting | USA | 0 |
NCT04923126 | Phase Ib/II | PD-0325901 | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | Recruiting | USA | 0 |
NCT04978727 | Phase I | SurVaxM | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | Recruiting | USA | CAN | 0 |
NCT05267106 | Phase II | Pemigatinib | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DNK | DEU | 1 |
NCT05297864 | Phase II | Niraparib | PARP Inhibition for Gliomas (PI-4G or pi4g) | Terminated | USA | 0 |
NCT05465954 | Phase II | NT-I7 + Pembrolizumab | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT05484622 | Phase I | Vorasidenib Pembrolizumab + Vorasidenib | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Glioma | Recruiting | USA | 0 |
NCT05538572 | Phase I | PRT3645 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | Completed | USA | 1 |
NCT05561374 | Phase I | OKN-007 | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma | Active, not recruiting | USA | 0 |
NCT06157541 | Phase Ib/II | CYT-101 + Pembrolizumab | T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma (TCaP) | Recruiting | AUS | 0 |
NCT06258018 | Phase Ib/II | Niraparib + Temozolomide | Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001) | Not yet recruiting | ITA | 0 |
NCT06504381 | Phase Ib/II | Toca FC + Vocimagene amiretrorepvec Temozolomide + Toca FC + Vocimagene amiretrorepvec | DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | Not yet recruiting | USA | 0 |
NCT06614855 | Phase I | C134-HSV-1 | A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma | Not yet recruiting | USA | 0 |